MeSH term
Frequency | Condition_Probility | Aged | 346 | 1.0 |
Aging/*metabolism | 9 | 4.0 |
Androgens/*deficiency | 3 | 100.0 |
Dehydroepiandrosterone Sulfate/blood | 66 | 78.0 |
Gonadal Steroid Hormones/blood | 36 | 53.0 |
Gonadotropins, Pituitary/blood | 16 | 47.0 |
*Hormone Replacement Therapy | 6 | 17.0 |
Humans | 1558 | 0.0 |
Hydrocortisone/blood | 47 | 11.0 |
Male | 637 | 0.0 |
Middle Aged | 608 | 1.0 |
beta-Endorphin/blood | 3 | 8.0 |
Adult | 883 | 1.0 |
Aged, 80 and over | 74 | 0.0 |
Aging/*physiology | 11 | 4.0 |
Longitudinal Studies | 34 | 3.0 |
Reference Values | 96 | 2.0 |
Research Support, U.S. Gov't, P.H.S. | 202 | 0.0 |
Testosterone/blood/*metabolism | 9 | 81.0 |
Bone Density/*physiology | 14 | 26.0 |
Chi-Square Distribution | 3 | 0.0 |
Exercise/*physiology | 15 | 3.0 |
Gonadal Steroid Hormones/*blood/physiology | 2 | 100.0 |
Multivariate Analysis | 17 | 1.0 |
Research Support, Non-U.S. Gov't | 679 | 0.0 |
Estrogens/physiology | 4 | 12.0 |
Female | 1075 | 1.0 |
Menopause/*physiology | 7 | 43.0 |
Patient Selection | 3 | 1.0 |
Adolescent | 251 | 1.0 |
Androstenedione/blood | 128 | 79.0 |
Body Constitution | 30 | 22.0 |
Body Mass Index | 137 | 13.0 |
Cyproterone Acetate/*therapeutic use | 5 | 100.0 |
Drug Therapy, Combination | 19 | 1.0 |
Ethinyl Estradiol/*therapeutic use | 5 | 55.0 |
Insulin Resistance | 27 | 15.0 |
Metformin/*therapeutic use | 9 | 39.0 |
Prospective Studies | 100 | 2.0 |
Sex Hormone-Binding Globulin/analysis | 262 | 93.0 |
Age Distribution | 7 | 2.0 |
Androgens/deficiency | 2 | 66.0 |
Incidence | 8 | 0.0 |
*Sex Characteristics | 7 | 4.0 |
Asia/ethnology | 2 | 6.0 |
Case-Control Studies | 84 | 1.0 |
Pedigree | 6 | 0.0 |
Postmenopause | 36 | 19.0 |
Premenopause | 12 | 12.0 |
Risk Assessment | 12 | 1.0 |
United States/epidemiology | 2 | 0.0 |
Biological Markers/*blood | 8 | 4.0 |
Carrier Proteins/blood | 7 | 6.0 |
Child, Preschool | 45 | 0.0 |
Comparative Study | 264 | 0.0 |
Infant | 18 | 0.0 |
Insulin/blood/physiology | 2 | 50.0 |
Insulin-Like Growth Factor I/analysis | 21 | 16.0 |
Prealbumin/analysis | 2 | 8.0 |
Serum Albumin/analysis | 20 | 11.0 |
Sex Hormone-Binding Globulin/*analysis | 211 | 100.0 |
Weight Gain | 8 | 12.0 |
3-Hydroxybutyric Acid/blood | 2 | 40.0 |
Dietary Carbohydrates/*pharmacology | 2 | 9.0 |
Energy Intake | 13 | 6.0 |
Insulin/*blood | 41 | 23.0 |
Testosterone/blood | 349 | 59.0 |
Thyroxine/*blood | 4 | 11.0 |
Triiodothyronine/blood | 30 | 14.0 |
Age Factors | 61 | 2.0 |
Biological Availability | 24 | 8.0 |
*Diet | 16 | 7.0 |
England | 3 | 2.0 |
*Life Style | 6 | 11.0 |
Nutritional Status | 4 | 2.0 |
Smoking/adverse effects | 5 | 1.0 |
Body Weight | 55 | 8.0 |
Endometrial Neoplasms/*blood/etiology | 2 | 100.0 |
Endometrium/pathology | 4 | 30.0 |
Gonadal Steroid Hormones/*blood | 120 | 80.0 |
Regression Analysis | 78 | 4.0 |
Risk Factors | 90 | 1.0 |
Sex Hormone-Binding Globulin/metabolism | 261 | 91.0 |
Amino Acid Substitution | 5 | 0.0 |
Base Sequence | 29 | 0.0 |
Binding Sites | 28 | 0.0 |
Crystallography, X-Ray | 6 | 0.0 |
DNA Primers | 4 | 0.0 |
Ligands | 12 | 0.0 |
Models, Molecular | 10 | 0.0 |
Mutagenesis, Site-Directed | 7 | 0.0 |
Protein Conformation | 10 | 0.0 |
Sex Hormone-Binding Globulin/*chemistry/genetics/*metabolism | 4 | 100.0 |
Steroids/*metabolism | 8 | 21.0 |
Substrate Specificity | 2 | 0.0 |
Variation (Genetics) | 8 | 0.0 |
Administration, Oral | 39 | 4.0 |
Androgens/*blood | 106 | 82.0 |
Drug Administration Schedule | 20 | 2.0 |
Polycystic Ovary Syndrome/*blood | 13 | 52.0 |
Dihydrotestosterone/metabolism | 26 | 48.0 |
In Vitro | 15 | 0.0 |
Protein Structure, Tertiary | 6 | 0.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Zinc/metabolism | 2 | 2.0 |
Contraceptives, Oral, Combined/*adverse effects | 3 | 30.0 |
Cyproterone Acetate | 6 | 42.0 |
Desogestrel | 24 | 82.0 |
Levonorgestrel | 24 | 72.0 |
Predictive Value of Tests | 19 | 0.0 |
Sex Hormone-Binding Globulin/*metabolism | 223 | 98.0 |
Alkaline Phosphatase/blood | 14 | 9.0 |
Amino Acids/urine | 4 | 13.0 |
Biological Markers/*analysis | 2 | 1.0 |
Bone Density | 13 | 10.0 |
Creatinine/urine | 3 | 2.0 |
Osteocalcin/blood | 13 | 17.0 |
Progesterone/blood | 53 | 21.0 |
Waist-Hip Ratio | 2 | 33.0 |
Animals | 86 | 0.0 |
Breast Neoplasms/*pathology | 2 | 0.0 |
Culture Media, Conditioned | 2 | 0.0 |
Estradiol/*metabolism | 18 | 28.0 |
Glycosylation | 11 | 1.0 |
Mice | 18 | 0.0 |
Mutation | 6 | 0.0 |
Protein Binding | 78 | 0.0 |
Tumor Cells, Cultured | 30 | 0.0 |
*Postmenopause | 14 | 21.0 |
Follicle Stimulating Hormone/*blood | 21 | 27.0 |
Luteinizing Hormone/*blood | 27 | 25.0 |
Oxygen Consumption | 2 | 0.0 |
Running/*physiology | 3 | 7.0 |
Testosterone/*blood | 219 | 78.0 |
Biological Markers/blood | 32 | 2.0 |
Estradiol/blood | 226 | 41.0 |
Italy/epidemiology | 3 | 1.0 |
*Polymorphism, Genetic | 6 | 0.0 |
Prostate/*metabolism | 9 | 12.0 |
RNA, Messenger/metabolism | 5 | 0.0 |
Sex Hormone-Binding Globulin/*biosynthesis/genetics | 3 | 100.0 |
Apolipoprotein A-I/blood | 6 | 5.0 |
Cholesterol/blood | 37 | 3.0 |
Contraceptives, Oral, Combined/*therapeutic use | 7 | 100.0 |
Cyproterone Acetate/therapeutic use | 2 | 22.0 |
Desogestrel/therapeutic use | 2 | 100.0 |
Ethinyl Estradiol/therapeutic use | 5 | 71.0 |
Lipids/*blood | 24 | 4.0 |
Lipoproteins, HDL Cholesterol/blood | 31 | 4.0 |
Lipoproteins, LDL Cholesterol/blood | 22 | 4.0 |
Severity of Illness Index | 11 | 0.0 |
Triglycerides/blood | 42 | 3.0 |
Androgens/*biosynthesis | 3 | 18.0 |
Androstenedione/metabolism | 4 | 13.0 |
Dehydroepiandrosterone Sulfate/metabolism | 2 | 20.0 |
Ovary/*metabolism | 4 | 7.0 |
Testosterone/metabolism | 22 | 17.0 |
Estradiol/administration & dosage | 4 | 33.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Growth Hormone/*blood | 6 | 3.0 |
Sex Factors | 26 | 1.0 |
Penile Erection/drug effects | 2 | 25.0 |
Spermatogenesis/drug effects | 5 | 35.0 |
Cross-Sectional Studies | 59 | 4.0 |
Estradiol/*blood | 89 | 58.0 |
Japan | 13 | 0.0 |
*Soybeans | 3 | 25.0 |
Aging/*blood | 14 | 19.0 |
Analysis of Variance | 38 | 1.0 |
Aging | 11 | 3.0 |
Dialysis | 4 | 9.0 |
Drug Stability | 3 | 1.0 |
False Negative Reactions | 2 | 1.0 |
False Positive Reactions | 2 | 0.0 |
Hypogonadism/blood/diagnosis | 2 | 100.0 |
Radioimmunoassay | 82 | 4.0 |
Sensitivity and Specificity | 15 | 0.0 |
Sex Hormone-Binding Globulin/analysis/metabolism | 5 | 83.0 |
Treatment Outcome | 18 | 0.0 |
Estradiol/biosynthesis | 2 | 11.0 |
Hormone Replacement Therapy | 5 | 13.0 |
Risk | 12 | 1.0 |
Sex Hormone-Binding Globulin/biosynthesis | 8 | 100.0 |
Time Factors | 76 | 0.0 |
*Sexual Behavior | 2 | 8.0 |
Adipose Tissue/metabolism | 7 | 5.0 |
Anthropometry | 36 | 15.0 |
Breast Neoplasms/epidemiology | 3 | 30.0 |
Comorbidity | 4 | 1.0 |
Estrogens/administration & dosage | 2 | 18.0 |
Life Style | 7 | 5.0 |
Survival Rate | 3 | 0.0 |
Health Status | 4 | 4.0 |
Hypogonadism/*complications | 2 | 50.0 |
Luteinizing Hormone/blood | 172 | 31.0 |
Questionnaires | 18 | 3.0 |
*Insulin Resistance | 28 | 14.0 |
Pregnancy/*physiology | 2 | 4.0 |
Pregnancy Trimester, First | 7 | 2.0 |
Alleles | 10 | 0.0 |
CHO Cells | 6 | 0.0 |
Deoxyribonuclease HpaII | 2 | 2.0 |
Exons | 10 | 0.0 |
Gene Deletion | 2 | 0.0 |
Gene Expression | 12 | 0.0 |
Hamsters | 8 | 0.0 |
Ovary/physiopathology | 3 | 18.0 |
Polycystic Ovary Syndrome/*genetics | 2 | 13.0 |
Polymorphism, Genetic | 4 | 0.0 |
Pregnancy | 81 | 1.0 |
Sex Hormone-Binding Globulin/*genetics | 24 | 96.0 |
*Variation (Genetics) | 6 | 0.0 |
Androgens/blood | 52 | 72.0 |
English Abstract | 76 | 0.0 |
Hypoglycemic Agents/therapeutic use | 3 | 6.0 |
Insulin/pharmacology | 3 | 1.0 |
Insulin-Like Growth Factor I/*analysis | 12 | 22.0 |
Metformin/therapeutic use | 4 | 40.0 |
Androgens/biosynthesis | 2 | 22.0 |
Child | 78 | 0.0 |
Chronic Disease | 8 | 0.0 |
Hypothalamo-Hypophyseal System/*physiopathology | 4 | 7.0 |
Testis/*physiopathology | 8 | 34.0 |
Hypothyroidism/*blood | 5 | 19.0 |
Isoelectric Focusing | 9 | 1.0 |
N-Acetylneuraminic Acid/analysis | 2 | 28.0 |
Sex Hormone-Binding Globulin/chemistry/*metabolism | 3 | 100.0 |
Thyroid Hormones/blood | 7 | 7.0 |
Adipose Tissue/*anatomy & histology | 9 | 16.0 |
Body Composition/physiology | 9 | 16.0 |
Body Constitution/*physiology | 6 | 46.0 |
Magnetic Resonance Imaging | 5 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 34 | 0.0 |
Skinfold Thickness | 9 | 12.0 |
Weight Lifting/*physiology | 3 | 18.0 |
Administration, Cutaneous | 15 | 15.0 |
*Estrogen Replacement Therapy | 26 | 24.0 |
Estrone/blood | 51 | 64.0 |
Medroxyprogesterone 17-Acetate/administration & dosage | 2 | 20.0 |
Biological Markers/blood/urine | 3 | 6.0 |
*Body Constitution | 7 | 25.0 |
Densitometry, X-Ray | 16 | 11.0 |
Osteoporosis/complications/*metabolism | 2 | 66.0 |
Biological Markers/analysis | 3 | 0.0 |
Body Composition | 25 | 10.0 |
Cohort Studies | 38 | 1.0 |
Diet, Fat-Restricted | 2 | 10.0 |
Gastroplasty | 2 | 33.0 |
Leptin/*metabolism | 2 | 11.0 |
Probability | 5 | 0.0 |
Weight Loss | 4 | 2.0 |
Cryptorchidism/*blood | 2 | 100.0 |
Pituitary Gland/physiopathology | 2 | 16.0 |
Postmenopause/*blood | 23 | 48.0 |
Premenopause/blood | 6 | 35.0 |
Statistics, Nonparametric | 10 | 0.0 |
Blood Glucose/analysis | 26 | 4.0 |
*Diet, Reducing | 8 | 11.0 |
*Energy Intake | 3 | 8.0 |
Insulin/blood | 82 | 12.0 |
Leptin/blood | 2 | 3.0 |
Luteinizing Hormone/blood/*secretion | 3 | 11.0 |
Periodicity | 2 | 4.0 |
Polycystic Ovary Syndrome/*complications | 6 | 75.0 |
Gonadotropins/blood | 16 | 50.0 |
Lisinopril/*pharmacology | 2 | 33.0 |
Polycystic Ovary Syndrome/*blood/complications | 6 | 75.0 |
Prolactin/blood | 65 | 11.0 |
Thyrotropin/blood | 35 | 8.0 |
Odds Ratio | 16 | 1.0 |
Androgens/metabolism | 12 | 19.0 |
Biological Markers | 11 | 0.0 |
Estradiol/metabolism | 10 | 10.0 |
Follicle Stimulating Hormone/*metabolism | 2 | 33.0 |
Ovarian Follicle/metabolism | 2 | 13.0 |
Reproduction/*physiology | 4 | 15.0 |
*Aromatase Inhibitors | 4 | 23.0 |
Drug Interactions | 8 | 0.0 |
Estrogens/blood | 22 | 44.0 |
Menopause | 43 | 19.0 |
Breast Neoplasms/*drug therapy/pathology | 3 | 7.0 |
Receptors, Estrogen/analysis | 5 | 1.0 |
Receptors, Progesterone/analysis | 4 | 1.0 |
Tamoxifen/administration & dosage/*pharmacology | 3 | 42.0 |
Triazoles/administration & dosage/*pharmacology | 2 | 50.0 |
Tumor Markers, Biological/*analysis | 3 | 0.0 |
*Climacteric | 3 | 75.0 |
Hyperinsulinism/*blood | 8 | 47.0 |
Area Under Curve | 9 | 1.0 |
Cross-Over Studies | 16 | 2.0 |
Double-Blind Method | 35 | 2.0 |
Ethinyl Estradiol/pharmacokinetics | 2 | 100.0 |
Serum Albumin/metabolism | 31 | 18.0 |
Follicle Stimulating Hormone/blood | 158 | 29.0 |
Heterozygote | 3 | 0.0 |
Homozygote | 3 | 0.0 |
Blood Glucose/metabolism | 28 | 3.0 |
Corticotropin/diagnostic use | 6 | 27.0 |
Hormones/blood | 23 | 21.0 |
Insulin-Like Growth Factor Binding Protein 1/*blood | 8 | 44.0 |
Insulin-Like Growth Factor Binding Protein 3/*blood | 3 | 11.0 |
Insulin-Like Growth Factor I/*metabolism | 18 | 13.0 |
Steroids/blood | 5 | 55.0 |
Anorexia Nervosa/*blood | 6 | 35.0 |
Thyroxine/blood | 34 | 13.0 |
Hysterectomy | 4 | 5.0 |
Menopause, Premature | 3 | 100.0 |
Ovariectomy | 5 | 4.0 |
Cholesterol/blood/*metabolism | 2 | 9.0 |
Arteriosclerosis/*etiology | 2 | 5.0 |
Blood Coagulation | 3 | 1.0 |
Insulin/metabolism | 5 | 3.0 |
Lipids/metabolism | 4 | 1.0 |
Orchiectomy/*adverse effects | 2 | 100.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
*Exercise | 6 | 4.0 |
Models, Genetic | 3 | 0.0 |
Sex Hormone-Binding Globulin/*genetics/*metabolism | 4 | 100.0 |
Cell Line | 13 | 0.0 |
Cell Membrane/metabolism | 12 | 0.0 |
Circular Dichroism | 2 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 15 | 0.0 |
Endometrium/metabolism | 5 | 9.0 |
Epididymis/metabolism | 2 | 14.0 |
Kinetics | 40 | 0.0 |
Polymerase Chain Reaction | 21 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 3 | 0.0 |
Sex Hormone-Binding Globulin/*genetics/metabolism | 9 | 100.0 |
Menstrual Cycle | 17 | 16.0 |
Ovulation | 5 | 9.0 |
Polycystic Ovary Syndrome/*metabolism | 11 | 42.0 |
DNA, Complementary | 4 | 0.0 |
Receptors, Androgen/genetics/*metabolism | 3 | 6.0 |
United States | 7 | 0.0 |
*Weight Lifting | 2 | 16.0 |
Retrospective Studies | 15 | 0.0 |
Androsterone/blood | 2 | 100.0 |
Dihydrotestosterone/blood | 50 | 70.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Steroids/*blood | 11 | 73.0 |
Estriol/blood | 4 | 12.0 |
*Postpartum Period | 2 | 5.0 |
Prolactin/*blood | 16 | 2.0 |
Menstruation/physiology | 2 | 25.0 |
Ovulation/physiology | 2 | 12.0 |
Reference Standards | 2 | 0.0 |
Glucose Tolerance Test | 49 | 11.0 |
Obesity/*complications | 5 | 29.0 |
Puberty/*metabolism | 2 | 28.0 |
Pregnancy Trimester, Third | 7 | 3.0 |
Apolipoproteins/blood | 5 | 2.0 |
Lipoproteins/*blood | 21 | 3.0 |
Prostate-Specific Antigen/*blood | 4 | 4.0 |
Receptors, Androgen/*genetics | 5 | 4.0 |
Enzyme-Linked Immunosorbent Assay | 8 | 0.0 |
Estrogens/deficiency | 2 | 66.0 |
Premenopause/*physiology | 4 | 30.0 |
Collagen/blood | 2 | 18.0 |
Hormones/*blood | 52 | 36.0 |
Peptides/blood | 3 | 8.0 |
*African Continental Ancestry Group | 6 | 5.0 |
*Anthropometry | 3 | 9.0 |
Circadian Rhythm | 5 | 1.0 |
*European Continental Ancestry Group | 4 | 4.0 |
Fasting | 15 | 4.0 |
Linear Models | 20 | 4.0 |
Mutation, Missense | 2 | 0.0 |
Sex Hormone-Binding Globulin/genetics | 3 | 100.0 |
Birth Weight | 3 | 1.0 |
Hemoglobin A, Glycosylated/metabolism | 3 | 2.0 |
Infant, Newborn | 13 | 0.0 |
*Diet, Fat-Restricted | 4 | 21.0 |
Dietary Fats/administration & dosage | 3 | 3.0 |
Dietary Fiber/*administration & dosage | 3 | 18.0 |
Autoradiography | 2 | 0.0 |
Isotope Labeling | 3 | 4.0 |
Ovarian Neoplasms/*metabolism | 3 | 5.0 |
Papio | 2 | 1.0 |
Prostatic Neoplasms/*metabolism | 4 | 3.0 |
Rabbits | 16 | 0.0 |
Rats | 36 | 0.0 |
Receptors, Cell Surface/*metabolism | 5 | 0.0 |
Species Specificity | 7 | 0.0 |
Tissue Distribution | 6 | 0.0 |
Tomography, Emission-Computed | 2 | 1.0 |
Amino Acid Sequence | 28 | 0.0 |
Molecular Sequence Data | 36 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
Thermodynamics | 4 | 1.0 |
Adipose Tissue/physiology | 4 | 18.0 |
Hydrocortisone/*blood | 23 | 16.0 |
Obesity/*blood/diet therapy | 3 | 37.0 |
Twins, Monozygotic | 3 | 3.0 |
Anticonvulsants/*therapeutic use | 4 | 28.0 |
Epilepsy/blood/*drug therapy | 3 | 60.0 |
Valproic Acid/*therapeutic use | 2 | 50.0 |
Thyroid Gland/*physiopathology | 2 | 7.0 |
Thyrotropin/*blood | 6 | 4.0 |
Triiodothyronine/*blood | 3 | 10.0 |
Dehydroepiandrosterone/blood | 50 | 69.0 |
Androgens/*physiology | 4 | 9.0 |
Estradiol/*physiology | 3 | 20.0 |
Sex Hormone-Binding Globulin/*physiology | 13 | 100.0 |
Vascular Resistance | 2 | 3.0 |
Insulin/blood/diagnostic use | 2 | 33.0 |
Insulin-Like Growth Factor Binding Protein 1/blood | 5 | 26.0 |
Polycystic Ovary Syndrome/*physiopathology | 2 | 28.0 |
Postpartum Period | 2 | 2.0 |
Blotting, Southern | 13 | 0.0 |
Cell Nucleus/metabolism | 5 | 0.0 |
DNA Footprinting | 2 | 0.0 |
Genes, Reporter | 3 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Transcription, Genetic | 11 | 0.0 |
Bone Remodeling | 2 | 10.0 |
Dimerization | 4 | 0.0 |
Bone Density/physiology | 3 | 14.0 |
Impotence/blood/etiology | 2 | 100.0 |
Insulin Resistance/*physiology | 11 | 14.0 |
Polycystic Ovary Syndrome/blood/*physiopathology | 2 | 40.0 |
Menstruation Disturbances/*etiology | 4 | 100.0 |
Ovary/ultrasonography | 4 | 57.0 |
Cognition/physiology | 2 | 6.0 |
*Body Composition | 9 | 8.0 |
Puberty | 12 | 16.0 |
Viscera | 6 | 19.0 |
Inhibins/*blood | 2 | 18.0 |
Sperm Count | 7 | 11.0 |
Sperm Motility | 3 | 6.0 |
Diagnosis, Differential | 7 | 0.0 |
Drug Resistance | 3 | 0.0 |
Thyroidectomy | 3 | 2.0 |
Thyrotropin/*secretion | 2 | 5.0 |
African Continental Ancestry Group | 7 | 2.0 |
Diet | 11 | 3.0 |
European Continental Ancestry Group | 17 | 2.0 |
Smoking | 16 | 4.0 |
Base Sequence/genetics | 3 | 0.0 |
Estrogen Receptor beta | 2 | 2.0 |
Blotting, Northern | 7 | 0.0 |
*Gene Expression Regulation | 3 | 0.0 |
Sex Hormone-Binding Globulin/biosynthesis/*genetics/metabolism | 2 | 100.0 |
Powders | 2 | 15.0 |
Hyperandrogenism/complications | 2 | 66.0 |
Insulin/*pharmacology | 5 | 2.0 |
Menstruation Disturbances/etiology | 3 | 37.0 |
Ovary/*blood supply | 2 | 40.0 |
Polycystic Ovary Syndrome/complications/*physiopathology | 3 | 75.0 |
Ultrasonography, Doppler, Color | 3 | 13.0 |
Androgen Antagonists/*therapeutic use | 5 | 13.0 |
Clomiphene/therapeutic use | 5 | 50.0 |
Ovulation Induction | 3 | 7.0 |
Polycystic Ovary Syndrome/complications/*drug therapy | 2 | 66.0 |
Smoking/*blood | 2 | 8.0 |
Data Interpretation, Statistical | 3 | 1.0 |
Sampling Studies | 2 | 1.0 |
Sex Hormone-Binding Globulin/*analysis/metabolism | 13 | 100.0 |
Testosterone/*blood/metabolism | 5 | 100.0 |
Saliva/*chemistry | 2 | 5.0 |
*Bone Density | 14 | 13.0 |
Femur | 2 | 10.0 |
Lumbosacral Region | 3 | 10.0 |
17-alpha-Hydroxyprogesterone/blood | 14 | 60.0 |
Corticotropin/blood | 4 | 2.0 |
Glycoproteins/*genetics | 4 | 2.0 |
Corticotropin/pharmacology | 4 | 7.0 |
Diet, Reducing | 5 | 15.0 |
Leptin/*blood | 8 | 10.0 |
Obesity/*blood/complications | 5 | 45.0 |
Socioeconomic Factors | 2 | 1.0 |
Clinical Trials | 17 | 1.0 |
Hormone Replacement Therapy/adverse effects/*methods | 2 | 40.0 |
Sexuality/drug effects/physiology | 2 | 100.0 |
Body Weight/physiology | 6 | 8.0 |
Calcitriol/blood | 2 | 4.0 |
Insulin-Like Growth Factor I/metabolism | 20 | 10.0 |
Parathyroid Hormone/*blood | 2 | 2.0 |
Immunoradiometric Assay | 8 | 7.0 |
Turner Syndrome/blood/*drug therapy | 2 | 50.0 |
Blood Pressure/physiology | 4 | 2.0 |
Insulin/blood/*physiology | 5 | 50.0 |
Insulin Resistance/physiology | 5 | 10.0 |
*Menopause | 20 | 37.0 |
Ovariectomy/adverse effects | 2 | 50.0 |
Polycystic Ovary Syndrome/complications | 5 | 100.0 |
Estrogen Replacement Therapy | 8 | 17.0 |
Sex Hormone-Binding Globulin/physiology | 2 | 100.0 |
Apolipoproteins B/blood | 11 | 4.0 |
Gonadotropins/*blood | 11 | 45.0 |
Lipoprotein(a)/blood | 3 | 4.0 |
Breast Neoplasms/*blood/etiology | 3 | 100.0 |
Nutrition | 2 | 5.0 |
Age of Onset | 3 | 0.0 |
Follow-Up Studies | 19 | 0.0 |
Obesity/*blood | 24 | 28.0 |
Sex Hormone-Binding Globulin | 7 | 100.0 |
beta-Endorphin/*blood | 2 | 14.0 |
Estrogens/*blood | 34 | 75.0 |
Calcium/metabolism | 4 | 0.0 |
*Complement Inactivators | 5 | 6.0 |
*Glycoproteins | 5 | 0.0 |
Molecular Conformation | 2 | 0.0 |
Receptors, Complement/metabolism | 2 | 3.0 |
Sequence Alignment | 5 | 0.0 |
Sex Hormone-Binding Globulin/*chemistry | 5 | 100.0 |
Structure-Activity Relationship | 11 | 0.0 |
Inhibins/blood | 2 | 22.0 |
Pregnancy Outcome | 4 | 1.0 |
Blood Coagulation/drug effects | 2 | 1.0 |
Blood Glucose/*metabolism | 12 | 4.0 |
Contraceptives, Oral/*adverse effects | 3 | 13.0 |
Breast Neoplasms/epidemiology/*etiology | 2 | 40.0 |
Parity | 4 | 3.0 |
Tumor Markers, Biological/*blood | 2 | 0.0 |
*Models, Biological | 3 | 1.0 |
Acne Vulgaris/*drug therapy | 2 | 66.0 |
Norpregnenes/pharmacology/*therapeutic use | 2 | 66.0 |
Progesterone Congeners/pharmacology/*therapeutic use | 2 | 50.0 |
Postmenopause/blood | 9 | 31.0 |
Sex Characteristics | 17 | 3.0 |
Androgens/physiology | 3 | 7.0 |
Drug Combinations | 14 | 2.0 |
Testosterone 5-alpha-Reductase/antagonists & inhibitors | 2 | 50.0 |
Norpregnenes/administration & dosage/*therapeutic use | 3 | 100.0 |
Ethinyl Estradiol/administration & dosage/*therapeutic use | 3 | 100.0 |
Hirsutism/blood/*drug therapy | 6 | 85.0 |
DNA Mutational Analysis | 3 | 0.0 |
Dihydrotestosterone/*metabolism | 12 | 80.0 |
Phosphorylation | 2 | 0.0 |
RNA, Messenger/analysis | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 6 | 0.0 |
Stanozolol/diagnostic use | 2 | 100.0 |
Lipids/blood | 27 | 4.0 |
Environment | 2 | 2.0 |
Ethnic Groups | 2 | 0.0 |
Alcohol Drinking/adverse effects | 2 | 4.0 |
Exercise | 6 | 5.0 |
Great Britain/epidemiology | 2 | 1.0 |
Premenopause/*blood | 7 | 38.0 |
Progesterone/*blood | 11 | 27.0 |
*Isoflavones | 4 | 25.0 |
Phytoestrogens | 6 | 22.0 |
Plant Preparations | 5 | 23.0 |
Isoflavones/administration & dosage/*therapeutic use | 2 | 100.0 |
Androgens/blood/*physiology | 2 | 100.0 |
Hyperandrogenism/*complications | 4 | 100.0 |
*Immunoassay | 2 | 14.0 |
*Fishes | 2 | 18.0 |
Gonadal Steroid Hormones/*blood/metabolism | 5 | 100.0 |
*Meat | 3 | 7.0 |
Bone Remodeling/*physiology | 3 | 12.0 |
Finland | 2 | 0.0 |
Alcohol Drinking | 15 | 11.0 |
Blotting, Western | 8 | 0.0 |
Breast Neoplasms/*metabolism/pathology | 3 | 1.0 |
Estradiol/pharmacology | 7 | 2.0 |
Protein Binding/drug effects | 6 | 1.0 |
RNA, Messenger/drug effects | 2 | 3.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Administration, Intravaginal | 7 | 35.0 |
Globulins/metabolism | 2 | 100.0 |
Liver/metabolism | 15 | 1.0 |
Progesterone/metabolism | 8 | 10.0 |
Reproducibility of Results | 14 | 0.0 |
Blood Pressure | 10 | 1.0 |
Hyperinsulinism/complications/*drug therapy | 3 | 75.0 |
Octreotide/*therapeutic use | 3 | 8.0 |
Abdomen | 5 | 5.0 |
Adipose Tissue/*metabolism | 2 | 1.0 |
Epidemiologic Studies | 2 | 4.0 |
Nuclear Family | 2 | 0.0 |
Body Composition/*drug effects | 2 | 15.0 |
Hyperandrogenism/*blood | 3 | 100.0 |
Puberty/*blood | 7 | 41.0 |
Sex Hormone-Binding Globulin/*analysis/genetics | 2 | 100.0 |
Drug Implants | 12 | 30.0 |
Estradiol/administration & dosage/blood/*therapeutic use | 2 | 100.0 |
Human Growth Hormone/blood | 7 | 12.0 |
Peptide Fragments/blood | 3 | 2.0 |
Procollagen/blood | 3 | 10.0 |
Bone Density/*drug effects | 3 | 10.0 |
Calcium/blood | 4 | 1.0 |
Hydroxyproline/urine | 2 | 11.0 |
Phosphates/blood | 2 | 3.0 |
Spironolactone/*therapeutic use | 3 | 42.0 |
Adipose Tissue/anatomy & histology | 4 | 14.0 |
Parathyroid Hormone/blood | 6 | 3.0 |
Dehydroepiandrosterone/administration & dosage/blood/*therapeutic use | 2 | 100.0 |
Dexamethasone/diagnostic use | 4 | 10.0 |
Obesity/physiopathology | 4 | 14.0 |
Progestins/blood | 4 | 80.0 |
Androstane-3,17-diol/analogs & derivatives/blood | 11 | 84.0 |
Dietary Proteins/*administration & dosage | 2 | 7.0 |
Aging/metabolism | 2 | 1.0 |
C-Peptide/blood | 14 | 8.0 |
Tomography, X-Ray Computed | 5 | 0.0 |
Chromatography, Affinity | 11 | 1.0 |
Phospholipids/metabolism | 2 | 1.0 |
*Blood Pressure | 2 | 1.0 |
Polycystic Ovary Syndrome/complications/*metabolism | 3 | 100.0 |
Body Composition/*physiology | 4 | 11.0 |
Muscle, Skeletal/*physiology | 2 | 2.0 |
Breast Neoplasms/blood/*metabolism | 2 | 33.0 |
Insulin-Like Growth Factor I/*biosynthesis | 2 | 18.0 |
Obesity | 3 | 5.0 |
Pilot Projects | 7 | 1.0 |
Hyperthyroidism/*physiopathology | 2 | 50.0 |
Osteocalcin/*blood | 2 | 9.0 |
Bone and Bones/*drug effects/*metabolism | 2 | 66.0 |
Contraceptives, Oral, Hormonal/*pharmacology | 4 | 33.0 |
Dietary Fiber/pharmacology | 2 | 50.0 |
Ethinyl Estradiol/*pharmacology | 7 | 41.0 |
Alopecia/*blood | 4 | 80.0 |
Acne Vulgaris/blood/*etiology | 2 | 100.0 |
Hirsutism/complications | 3 | 100.0 |
Menstruation Disturbances/complications | 2 | 100.0 |
Dehydroepiandrosterone Sulfate/*blood | 10 | 71.0 |
Menopause/*blood | 15 | 60.0 |
Menstruation | 10 | 16.0 |
Sex Hormone-Binding Globulin/analysis/*metabolism | 6 | 100.0 |
Contraceptive Agents, Male/*pharmacology | 3 | 75.0 |
Feasibility Studies | 2 | 0.0 |
Sexual Behavior/drug effects | 3 | 75.0 |
Testis/anatomy & histology/drug effects | 2 | 100.0 |
Testosterone/*analogs & derivatives/blood/pharmacology | 2 | 66.0 |
Norgestrel/pharmacology | 5 | 55.0 |
Concanavalin A/metabolism | 3 | 11.0 |
Estrone/*blood | 8 | 72.0 |
Single-Blind Method | 5 | 2.0 |
Ethinyl Estradiol/*administration & dosage/adverse effects | 2 | 100.0 |
Obesity/*blood/complications/diagnosis | 2 | 100.0 |
Polycystic Ovary Syndrome/*blood/complications/diagnosis | 3 | 100.0 |
*Obesity | 3 | 5.0 |
Estrone/metabolism | 3 | 23.0 |
Obesity/complications | 7 | 14.0 |
Diabetes Mellitus, Type 2/blood/*epidemiology | 2 | 100.0 |
Heart Diseases/epidemiology | 2 | 66.0 |
Massachusetts/epidemiology | 3 | 27.0 |
Fasting/blood | 2 | 3.0 |
Hypoglycemic Agents/*therapeutic use | 8 | 14.0 |
Polycystic Ovary Syndrome/blood/*complications | 3 | 75.0 |
Antineoplastic Agents, Hormonal/*therapeutic use | 3 | 4.0 |
Blood Proteins/*analysis | 4 | 2.0 |
Chemotherapy, Adjuvant | 3 | 1.0 |
Tamoxifen/*therapeutic use | 5 | 6.0 |
*Contraceptives, Oral | 2 | 33.0 |
Homeostasis | 8 | 2.0 |
Inflammation Mediators/blood | 2 | 4.0 |
Breast Neoplasms/blood/*drug therapy | 3 | 50.0 |
Dose-Response Relationship, Drug | 44 | 0.0 |
Endocrine Glands/*drug effects | 3 | 37.0 |
Immunoassay | 4 | 1.0 |
Tritium/diagnostic use | 2 | 1.0 |
Electromyography | 5 | 2.0 |
Lactates/blood | 3 | 4.0 |
Muscle Contraction/*physiology | 2 | 4.0 |
Carbamazepine/pharmacology/therapeutic use | 4 | 100.0 |
Phenytoin/pharmacology/therapeutic use | 3 | 75.0 |
Ovary/metabolism | 5 | 6.0 |
*Ovulation Induction | 6 | 14.0 |
Norethindrone/*pharmacokinetics | 2 | 100.0 |
Placebos | 13 | 5.0 |
Contraceptives, Oral/pharmacology | 2 | 11.0 |
Estrogens/pharmacology | 3 | 3.0 |
Menopause/*metabolism | 3 | 25.0 |
*Hysterectomy | 2 | 18.0 |
Menopause/blood | 9 | 50.0 |
Biological Transport, Active | 2 | 1.0 |
*Intercellular Signaling Peptides and Proteins | 6 | 1.0 |
Prostatic Neoplasms/blood/*drug therapy | 3 | 20.0 |
Australia | 2 | 1.0 |
China | 5 | 1.0 |
Prostate/*anatomy & histology | 2 | 100.0 |
Prostate-Specific Antigen/blood | 3 | 3.0 |
Escherichia coli/genetics | 2 | 0.0 |
Disease Susceptibility | 2 | 0.0 |
Japan/ethnology | 2 | 2.0 |
Hypercholesterolemia/blood/*drug therapy | 2 | 8.0 |
Cholesterol/*blood | 6 | 2.0 |
Lipoproteins, HDL Cholesterol/*blood | 10 | 4.0 |
Testis/*physiology | 6 | 15.0 |
Triglycerides/*blood | 3 | 0.0 |
Alcohol Drinking/blood | 2 | 18.0 |
Weight Loss/physiology | 2 | 10.0 |
RNA, Messenger/*analysis | 3 | 0.0 |
Carrier Proteins/metabolism | 8 | 1.0 |
Human Growth Hormone/*deficiency | 2 | 9.0 |
Insulin-Like Growth Factor Binding Protein 3/blood | 9 | 16.0 |
Polycystic Ovary Syndrome/complications/*diagnosis | 2 | 66.0 |
Anovulation | 2 | 100.0 |
Hyperinsulinism | 3 | 33.0 |
Factor VII/analysis | 2 | 6.0 |
Fibrinogen/analysis | 4 | 2.0 |
Carrier Proteins/*blood | 11 | 4.0 |
Thyroxine-Binding Proteins/*analysis | 2 | 66.0 |
Pre-Eclampsia/*metabolism | 2 | 9.0 |
Uric Acid/blood | 2 | 3.0 |
Acne Vulgaris/blood/*drug therapy | 2 | 100.0 |
Amenorrhea/*blood | 4 | 22.0 |
Flutamide/*therapeutic use | 2 | 28.0 |
Oligomenorrhea/*blood | 2 | 66.0 |
Progestins/administration & dosage | 2 | 16.0 |
Prevalence | 6 | 0.0 |
Sympathetic Nervous System/*physiopathology | 2 | 5.0 |
Breast/cytology/*drug effects | 2 | 22.0 |
Breast Neoplasms/blood/drug therapy/*prevention & control | 2 | 100.0 |
Cell Division/drug effects | 8 | 0.0 |
Epithelium/drug effects | 2 | 4.0 |
Fibroadenoma/blood/drug therapy/*prevention & control | 2 | 100.0 |
Proliferating Cell Nuclear Antigen/metabolism | 2 | 0.0 |
Tamoxifen/*administration & dosage/pharmacology/therapeutic use | 2 | 100.0 |
Interleukin-6/adverse effects/*therapeutic use | 2 | 100.0 |
Pituitary Gland/*drug effects | 4 | 28.0 |
Recombinant Proteins/adverse effects/therapeutic use | 2 | 6.0 |
Testis/*drug effects | 4 | 36.0 |
Follicle Stimulating Hormone/metabolism | 6 | 24.0 |
Lipoproteins, VLDL/blood | 3 | 1.0 |
Lipoproteins/blood | 9 | 2.0 |
*Premenopause | 4 | 20.0 |
Breast Neoplasms/*metabolism | 8 | 2.0 |
Cattle | 9 | 0.0 |
Cyclic AMP/*metabolism | 5 | 2.0 |
Estradiol/*pharmacology | 8 | 3.0 |
Pituitary Hormones/blood | 3 | 42.0 |
Biopsy | 3 | 0.0 |
Vagina/cytology/drug effects | 2 | 100.0 |
Evaluation Studies | 5 | 0.0 |
Hyperthyroidism/blood | 8 | 42.0 |
Methods | 5 | 2.0 |
Osmolar Concentration | 18 | 2.0 |
Aging/blood/metabolism/*physiology | 2 | 66.0 |
Patient Compliance | 3 | 1.0 |
Postmenopause/*metabolism | 9 | 37.0 |
Syndrome | 4 | 0.0 |
Urban Health | 3 | 7.0 |
Leydig Cells/*physiology | 4 | 50.0 |
Fetal Blood/*chemistry | 3 | 5.0 |
Transcortin/*metabolism | 10 | 90.0 |
Danazol/*therapeutic use | 3 | 27.0 |
Estrogen Antagonists/*therapeutic use | 2 | 10.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 2 | 0.0 |
Aromatase Inhibitors | 2 | 10.0 |
Neoplasm Metastasis | 3 | 0.0 |
Neoplasm Staging | 9 | 0.0 |
Follicular Phase/blood | 3 | 50.0 |
Norethindrone/therapeutic use | 2 | 40.0 |
Leptin | 12 | 11.0 |
Proteins/*metabolism | 9 | 1.0 |
Aging/physiology | 3 | 1.0 |
Sex Hormone-Binding Globulin/analysis/*genetics | 3 | 100.0 |
Testis/physiology | 3 | 8.0 |
Breast Neoplasms/*drug therapy/metabolism | 3 | 11.0 |
Acne Vulgaris/*blood | 3 | 100.0 |
Laparoscopy/*methods | 2 | 15.0 |
Aromatase/*genetics | 2 | 8.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Genotype | 6 | 0.0 |
Body Height | 10 | 6.0 |
*Puberty | 9 | 37.0 |
Point Mutation | 3 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Sex Hormone-Binding Globulin/chemistry/*genetics/metabolism | 3 | 100.0 |
Androstenedione/*blood | 11 | 61.0 |
Prognosis | 16 | 0.0 |
Signal Transduction/*physiology | 2 | 0.0 |
Cell Division | 2 | 0.0 |
Sex Hormone-Binding Globulin/genetics/*metabolism | 2 | 100.0 |
Transfection | 3 | 0.0 |
Cyclic AMP/biosynthesis | 2 | 1.0 |
GTP-Binding Proteins/*metabolism | 2 | 0.0 |
*Signal Transduction | 2 | 0.0 |
*Antibodies, Monoclonal | 2 | 0.0 |
Antibody Specificity | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 3 | 2.0 |
Hybridomas/immunology | 2 | 1.0 |
Sex Hormone-Binding Globulin/*analysis/immunology | 4 | 100.0 |
DNA/chemistry | 4 | 1.0 |
DNA Primers/chemistry | 2 | 0.0 |
Electrophoresis, Agar Gel | 9 | 1.0 |
Luteinizing Hormone/blood/secretion | 4 | 22.0 |
Hypothalamo-Hypophyseal System/physiopathology | 2 | 5.0 |
Finasteride/*therapeutic use | 3 | 37.0 |
Hirsutism/*drug therapy | 8 | 88.0 |
Hypothyroidism/blood/*drug therapy | 3 | 60.0 |
Peptide Fragments/*blood | 3 | 3.0 |
Procollagen/*blood | 2 | 12.0 |
Thyroxine/*therapeutic use | 3 | 16.0 |
Immunohistochemistry | 2 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
*Alternative Splicing | 2 | 0.0 |
RNA, Messenger/*genetics | 3 | 0.0 |
Creatinine/blood | 2 | 0.0 |
Luteinizing Hormone/metabolism | 5 | 18.0 |
Confidence Intervals | 3 | 0.0 |
Logistic Models | 15 | 2.0 |
Osteoporosis/*blood | 2 | 40.0 |
*Fertilization in Vitro | 6 | 5.0 |
Follicular Fluid/*chemistry | 3 | 12.0 |
Glucocorticoids/*therapeutic use | 2 | 5.0 |
Polycystic Ovary Syndrome/blood/complications/*drug therapy | 2 | 100.0 |
Antineoplastic Combined Chemotherapy Protocols/*adverse effects | 4 | 9.0 |
Mechlorethamine/adverse effects | 2 | 100.0 |
Prednisolone/adverse effects | 2 | 40.0 |
Procarbazine/adverse effects | 2 | 66.0 |
Vinblastine/adverse effects | 2 | 66.0 |
Contraceptive Agents, Female/*administration & dosage | 2 | 50.0 |
Intrauterine Devices, Copper | 2 | 66.0 |
*Intrauterine Devices, Medicated | 4 | 66.0 |
Levonorgestrel/*administration & dosage | 2 | 50.0 |
Androgens/*metabolism | 13 | 22.0 |
Estrogens/*metabolism | 4 | 7.0 |
Iodine Radioisotopes/diagnostic use | 5 | 1.0 |
Breast Neoplasms | 2 | 0.0 |
Fluoroimmunoassay | 4 | 9.0 |
Spermatogenesis/*drug effects | 2 | 25.0 |
Thyroid Diseases/*blood | 2 | 22.0 |
Hypoglycemic Agents/*pharmacology | 2 | 4.0 |
Metabolic Clearance Rate | 15 | 4.0 |
*Thiazolidinediones | 4 | 4.0 |
Half-Life | 11 | 1.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Adipose Tissue/*physiology | 4 | 22.0 |
Chorionic Gonadotropin/blood | 4 | 4.0 |
Orchiectomy | 11 | 10.0 |
Semen/*physiology | 2 | 20.0 |
Spermatogenesis | 2 | 3.0 |
Asian Continental Ancestry Group | 4 | 1.0 |
Oligomenorrhea/blood | 2 | 50.0 |
ROC Curve | 2 | 1.0 |
Blood Glucose | 3 | 3.0 |
Hair/*growth & development | 3 | 37.0 |
*Body Mass Index | 7 | 8.0 |
Hormones/*metabolism | 2 | 8.0 |
Obesity/metabolism | 3 | 6.0 |
*Glucose Tolerance Test | 3 | 5.0 |
Obesity/blood | 7 | 20.0 |
Chromatography, High Pressure Liquid | 6 | 0.0 |
Diabetes Mellitus, Type 1/*blood | 4 | 2.0 |
Hemoglobin A, Glycosylated/analysis | 4 | 0.0 |
Proteins/*analysis | 8 | 5.0 |
Androgen-Binding Protein/blood | 2 | 100.0 |
Anticonvulsants/*pharmacology/therapeutic use | 3 | 60.0 |
Educational Status | 2 | 3.0 |
Marital Status | 2 | 18.0 |
Sexual Behavior/*drug effects | 5 | 71.0 |
Sex Hormone-Binding Globulin/*deficiency | 2 | 100.0 |
Graves' Disease/blood | 4 | 40.0 |
Hyperthyroidism/*blood/etiology | 2 | 100.0 |
Luteinizing Hormone/*secretion | 3 | 11.0 |
*Running | 7 | 25.0 |
Hypogonadism/*drug therapy | 4 | 66.0 |
Injections, Intramuscular | 3 | 1.0 |
Testosterone/administration & dosage/*analogs & | 2 | 100.0 |
Hirsutism/blood/*diagnosis | 2 | 100.0 |
Polycystic Ovary Syndrome/blood/*diagnosis | 2 | 100.0 |
Transcortin/*analysis | 5 | 55.0 |
Chromatography, Gel | 10 | 1.0 |
Magnetic Resonance Spectroscopy | 3 | 0.0 |
Fertility/*physiology | 2 | 13.0 |
Infertility, Female/*metabolism | 2 | 25.0 |
Amenorrhea/*etiology | 2 | 22.0 |
Menstrual Cycle/*physiology | 2 | 3.0 |
Diabetes Mellitus, Type 2 | 2 | 33.0 |
Cholestenone 5 alpha-Reductase | 3 | 11.0 |
Enzyme Inhibitors/*therapeutic use | 2 | 2.0 |
Carcinoma, Hepatocellular | 6 | 1.0 |
Liver Neoplasms | 8 | 2.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
Sequence Deletion | 4 | 0.0 |
Sequence Homology, Nucleic Acid | 6 | 0.0 |
Sex Hormone-Binding Globulin/biosynthesis/*genetics | 3 | 100.0 |
Hypothalamo-Hypophyseal System/*drug effects | 5 | 26.0 |
Gonadorelin/diagnostic use | 8 | 13.0 |
Gonadal Steroid Hormones/pharmacology | 2 | 25.0 |
Libido/drug effects | 3 | 27.0 |
Estradiol/*administration & dosage | 2 | 16.0 |
Estrogens/*urine | 5 | 71.0 |
*Dietary Fiber | 4 | 50.0 |
Physical Endurance/*physiology | 5 | 11.0 |
Europe/ethnology | 2 | 2.0 |
Binding, Competitive | 24 | 1.0 |
Carrier Proteins | 2 | 3.0 |
Sex Hormone-Binding Globulin/*pharmacology | 11 | 100.0 |
Adipose Tissue | 9 | 17.0 |
Adrenal Cortex Hormones/*blood | 10 | 58.0 |
Food | 3 | 2.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
Factor VIIIa/metabolism | 2 | 13.0 |
Factor Va/metabolism | 2 | 6.0 |
Sex Hormone-Binding Globulin/*metabolism/physiology | 3 | 100.0 |
Exons/*genetics | 2 | 0.0 |
Polymerase Chain Reaction/methods | 5 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Breast Neoplasms/*drug therapy | 3 | 4.0 |
Human Growth Hormone/*blood | 2 | 6.0 |
Postmenopause/metabolism | 3 | 27.0 |
Body Weight/*physiology | 5 | 16.0 |
Sex Distribution | 4 | 1.0 |
Smoking/*adverse effects | 2 | 0.0 |
Lactic Acid/blood | 2 | 4.0 |
Insulin/*metabolism | 3 | 3.0 |
Testosterone/*metabolism | 12 | 33.0 |
Phenotype | 8 | 0.0 |
8-Bromo Cyclic Adenosine Monophosphate/pharmacology | 2 | 2.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Culture Techniques | 3 | 0.0 |
Dihydrotestosterone/pharmacology | 3 | 3.0 |
Tamoxifen/therapeutic use | 3 | 4.0 |
Liver/*metabolism | 6 | 1.0 |
Prednisone/therapeutic use | 2 | 1.0 |
*Dietary Supplements | 3 | 5.0 |
Somatomedins/metabolism | 5 | 17.0 |
Weight Loss/*physiology | 4 | 12.0 |
RNA, Messenger/*biosynthesis | 3 | 1.0 |
Injections, Intravenous | 7 | 1.0 |
Insulin/*secretion | 3 | 3.0 |
Chorionic Gonadotropin/therapeutic use | 5 | 16.0 |
Fertilization in Vitro | 4 | 3.0 |
Cell Division/physiology | 2 | 0.0 |
Receptors, Cell Surface/*physiology | 2 | 0.0 |
Hyperandrogenism/*drug therapy/metabolism | 2 | 100.0 |
Obesity/*drug therapy/metabolism | 2 | 50.0 |
Polycystic Ovary Syndrome/*drug therapy | 5 | 50.0 |
Heart Rate/physiology | 3 | 3.0 |
Postmenopause/*physiology | 2 | 8.0 |
*Reproduction | 2 | 10.0 |
C-Peptide/*blood | 3 | 8.0 |
Testosterone/blood/metabolism | 4 | 57.0 |
Polycystic Ovary Syndrome/*blood/pathology | 3 | 100.0 |
Antibodies, Monoclonal | 4 | 0.0 |
Protein C/metabolism | 2 | 2.0 |
Protein S/*chemistry | 2 | 100.0 |
Recombinant Proteins | 4 | 0.0 |
Hypoglycemic Agents/administration & dosage/*therapeutic use | 2 | 22.0 |
Metformin/administration & dosage/*therapeutic use | 2 | 50.0 |
Polycystic Ovary Syndrome/blood/*drug therapy | 4 | 36.0 |
Alternative Splicing/genetics | 2 | 1.0 |
Reagent Kits, Diagnostic | 2 | 1.0 |
Estradiol/*blood/metabolism | 2 | 100.0 |
Receptors, Estrogen/metabolism | 5 | 1.0 |
Alcoholism/blood | 2 | 28.0 |
Sweden/epidemiology | 4 | 3.0 |
*Estrogen Replacement Therapy/adverse effects | 2 | 20.0 |
Molecular Structure | 4 | 0.0 |
Charcoal | 4 | 15.0 |
Immunoenzyme Techniques | 3 | 0.0 |
DNA | 3 | 0.0 |
*Exons | 4 | 1.0 |
Leiomyoma/*metabolism | 2 | 12.0 |
Estradiol Congeners/*therapeutic use | 2 | 66.0 |
Breast Neoplasms/prevention & control | 2 | 25.0 |
DNA Primers/genetics | 2 | 0.0 |
Endometrium/*metabolism | 3 | 3.0 |
RNA, Messenger/*genetics/*metabolism | 2 | 4.0 |
Chromosome Mapping | 5 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Mice, Transgenic | 3 | 0.0 |
Organ Specificity/genetics | 2 | 1.0 |
Androstane-3,17-diol/blood | 3 | 100.0 |
Hyperthyroidism/*blood | 3 | 15.0 |
Insulin/*blood/secretion | 2 | 16.0 |
*Adrenal Hyperplasia, Congenital | 3 | 13.0 |
Gene Frequency | 6 | 0.0 |
Cyclic AMP/physiology | 2 | 1.0 |
Dogs | 2 | 0.0 |
*Electronics | 2 | 66.0 |
Danazol/*pharmacology | 2 | 28.0 |
Estrogen Antagonists/*pharmacology | 2 | 2.0 |
Progesterone/*pharmacology | 2 | 2.0 |
Haplorhini | 2 | 0.0 |
Swine | 2 | 0.0 |
Diabetes Mellitus, Type 2/*blood/epidemiology | 2 | 100.0 |
Metabolic Syndrome X/*blood/epidemiology | 2 | 66.0 |
Hirsutism/*blood | 12 | 92.0 |
Hospitalization | 2 | 1.0 |
Substance Withdrawal Syndrome/*blood | 2 | 50.0 |
Hypogonadism/blood/drug therapy/*metabolism | 2 | 66.0 |
Contraceptives, Oral/*administration & dosage | 7 | 70.0 |
Family | 2 | 0.0 |
Sex Hormone-Binding Globulin/analysis/*biosynthesis | 3 | 100.0 |
Estradiol Congeners/*pharmacology | 2 | 22.0 |
Sex Hormone-Binding Globulin/*biosynthesis | 10 | 100.0 |
Tamoxifen/*pharmacology | 2 | 3.0 |
Pituitary Gland/*metabolism | 2 | 5.0 |
Antithrombin III/analysis | 2 | 1.0 |
Blood Coagulation Factors/*analysis | 2 | 2.0 |
Obesity/blood/physiopathology | 2 | 25.0 |
Plasminogen Activator Inhibitor 1/blood | 2 | 1.0 |
Protein C/analysis | 3 | 5.0 |
Albumins/*metabolism | 2 | 22.0 |
Blood Proteins/metabolism | 11 | 5.0 |
Sex Hormone-Binding Globulin/isolation & purification/*metabolism | 6 | 100.0 |
Glucose Clamp Technique | 7 | 6.0 |
Sex Hormone-Binding Globulin/drug effects/*metabolism | 2 | 100.0 |
Gonadal Steroid Hormones/*metabolism | 7 | 46.0 |
Thyrotropin/metabolism | 2 | 3.0 |
Immunoassay/*methods | 3 | 3.0 |
Hypogonadism/*blood/drug therapy | 2 | 66.0 |
Testosterone/*blood/therapeutic use | 2 | 100.0 |
Growth Hormone/*deficiency | 2 | 6.0 |
Labor, Obstetric | 2 | 4.0 |
Seasons | 2 | 1.0 |
Androstenediol/blood | 5 | 100.0 |
Lipoproteins, HDL/blood | 9 | 3.0 |
Aging/blood | 8 | 14.0 |
Singapore | 2 | 4.0 |
Cortodoxone/blood | 2 | 50.0 |
Ovary/drug effects | 7 | 46.0 |
*Blood Chemical Analysis | 2 | 20.0 |
Dihydrotestosterone/*blood | 15 | 78.0 |
Menarche/*blood | 2 | 100.0 |
Estradiol/*therapeutic use | 4 | 36.0 |
Serum Albumin/*metabolism | 8 | 16.0 |
Recombinant Fusion Proteins/metabolism | 3 | 0.0 |
Estrone/analogs & derivatives/blood | 9 | 100.0 |
Adipose Tissue/pathology | 2 | 6.0 |
Endocrine Glands/physiopathology | 3 | 27.0 |
Obesity/complications/pathology | 3 | 60.0 |
*Physical Education and Training | 3 | 5.0 |
*Weight Loss | 4 | 8.0 |
DNA/biosynthesis | 2 | 0.0 |
Models, Structural | 2 | 1.0 |
Sex Hormone-Binding Globulin/*chemistry/metabolism | 3 | 100.0 |
Immunoblotting | 2 | 0.0 |
Factor X/chemistry | 2 | 50.0 |
Obesity/diet therapy/*metabolism | 2 | 28.0 |
Adrenal Glands/physiopathology | 2 | 25.0 |
Diazoxide/pharmacology | 2 | 33.0 |
Insulin/physiology | 3 | 9.0 |
Acute Disease | 2 | 0.0 |
Obesity/*blood/physiopathology | 3 | 25.0 |
Hirsutism/etiology | 3 | 60.0 |
Insulin/*physiology | 6 | 13.0 |
Models, Biological | 5 | 0.0 |
Contraceptives, Oral/*pharmacology | 8 | 36.0 |
Gonadorelin/*pharmacology | 3 | 8.0 |
Hirsutism/*metabolism | 4 | 100.0 |
California | 2 | 4.0 |
Epidermal Growth Factor/pharmacology | 2 | 0.0 |
Organ Culture Techniques | 2 | 0.0 |
Sex Hormone-Binding Globulin/*secretion | 3 | 100.0 |
Testosterone/*pharmacology | 5 | 16.0 |
Triiodothyronine/*pharmacology | 2 | 4.0 |
Receptors, Androgen/*metabolism | 8 | 7.0 |
Prostatic Neoplasms/*blood | 6 | 23.0 |
Absorptiometry, Photon | 2 | 33.0 |
Bone Density/drug effects | 2 | 7.0 |
Testosterone/blood/*therapeutic use | 3 | 50.0 |
Growth Hormone/secretion | 2 | 2.0 |
Luteinizing Hormone/secretion | 2 | 4.0 |
Secretory Rate/drug effects | 2 | 2.0 |
*Aging | 10 | 6.0 |
Osteoporosis/*metabolism | 2 | 50.0 |
Chorionic Gonadotropin/*diagnostic use | 2 | 100.0 |
Ethinyl Estradiol/pharmacology | 10 | 38.0 |
Receptors, Estrogen/*metabolism | 2 | 0.0 |
Bone and Bones/drug effects/*metabolism | 2 | 33.0 |
Breast Neoplasms/*blood/epidemiology | 2 | 66.0 |
Guernsey | 2 | 100.0 |
Breast Neoplasms/*epidemiology | 2 | 18.0 |
Postmenopause/*blood/physiology | 3 | 100.0 |
Adipose Tissue/radiography | 2 | 66.0 |
Dehydroepiandrosterone/*blood | 4 | 22.0 |
Chromatography | 2 | 1.0 |
Chorionic Gonadotropin/*blood | 3 | 3.0 |
Absorption | 2 | 1.0 |
Menstrual Cycle/*blood | 3 | 21.0 |
Molecular Weight | 6 | 0.0 |
Exons/genetics | 3 | 0.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Obesity/*physiopathology | 3 | 5.0 |
Spine | 2 | 22.0 |
Calcium/urine | 2 | 7.0 |
Transcortin/metabolism | 8 | 88.0 |
Dietary Fats/*administration & dosage | 2 | 2.0 |
Concanavalin A | 5 | 10.0 |
Isomerism | 3 | 1.0 |
Dihydrotestosterone/*pharmacology | 3 | 9.0 |
Obesity/*metabolism | 6 | 8.0 |
Postmenopause/*drug effects | 2 | 66.0 |
Bone and Bones/*metabolism | 5 | 7.0 |
Endometrial Neoplasms/*blood | 2 | 50.0 |
Estrogens, Conjugated (USP)/blood | 2 | 66.0 |
Blood Glucose/*analysis | 4 | 3.0 |
Adrenal Cortex/*physiology | 2 | 22.0 |
Dexamethasone/*therapeutic use | 3 | 16.0 |
Gestational Age | 3 | 0.0 |
Steroids/metabolism | 4 | 12.0 |
Exercise Test | 2 | 0.0 |
*Exertion | 2 | 1.0 |
Survival Analysis | 3 | 0.0 |
Stereoisomerism | 3 | 0.0 |
Thyroxine-Binding Proteins/metabolism | 3 | 21.0 |
Gonadorelin/pharmacology | 5 | 11.0 |
Protirelin/pharmacology | 2 | 1.0 |
Patient Satisfaction | 2 | 5.0 |
Diabetes Mellitus, Type 2/*blood | 3 | 2.0 |
Saliva/*metabolism | 5 | 15.0 |
Estradiol/blood/*therapeutic use | 2 | 100.0 |
Gonadotropins, Pituitary/*blood | 21 | 38.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Puberty/physiology | 2 | 13.0 |
Contraceptives, Oral/*therapeutic use | 2 | 28.0 |
Goserelin/*therapeutic use | 3 | 37.0 |
Ovary/*surgery | 2 | 40.0 |
Exercise/physiology | 4 | 6.0 |
*Physical Fitness | 2 | 5.0 |
Muscles/physiology | 2 | 15.0 |
Urea/blood | 2 | 6.0 |
Obesity/blood/*complications | 5 | 62.0 |
Disease Progression | 2 | 0.0 |
Dehydroepiandrosterone/analogs & derivatives/blood | 44 | 70.0 |
Dehydroepiandrosterone Sulfate | 62 | 63.0 |
Growth Hormone/blood | 11 | 4.0 |
Smoking/blood | 5 | 12.0 |
Matched-Pair Analysis | 3 | 3.0 |
Reproduction | 2 | 9.0 |
Polycystic Ovary Syndrome/*blood/drug therapy | 3 | 75.0 |
Menstrual Cycle/metabolism | 3 | 13.0 |
Cardiovascular Diseases/blood | 3 | 15.0 |
Liver Diseases/blood | 2 | 7.0 |
Sexual Maturation | 2 | 8.0 |
Sperm Count/drug effects | 3 | 30.0 |
17-alpha-Hydroxyprogesterone | 20 | 45.0 |
Hydroxyprogesterones/blood | 22 | 45.0 |
Luteal Phase | 7 | 10.0 |
Acne Vulgaris/blood/*drug therapy/pathology | 2 | 100.0 |
Insulin-Like Growth Factor Binding Protein 1/*metabolism | 2 | 40.0 |
Dehydroepiandrosterone/*analogs & derivatives/blood | 14 | 82.0 |
Estradiol/analysis/blood | 3 | 100.0 |
Follicular Fluid/chemistry | 2 | 20.0 |
Progesterone/analysis/blood | 2 | 100.0 |
Testosterone/analysis/blood | 3 | 100.0 |
Hyperinsulinism/*metabolism | 2 | 40.0 |
Fetal Blood | 2 | 1.0 |
*Genes | 2 | 0.0 |
Cardiovascular Diseases | 2 | 40.0 |
Puberty/blood | 2 | 40.0 |
Running | 3 | 8.0 |
Norway | 4 | 3.0 |
Injections, Subcutaneous | 3 | 0.0 |
Recombinant Proteins/administration & dosage/pharmacology | 2 | 3.0 |
*Postmenopause/blood | 2 | 66.0 |
Dietary Proteins | 2 | 14.0 |
Rural Population | 2 | 2.0 |
Ethinyl Estradiol/administration & dosage | 3 | 50.0 |
Estrogens/*physiology | 2 | 5.0 |
Prostatic Hyperplasia/metabolism | 2 | 6.0 |
Hirsutism/*blood/complications | 2 | 100.0 |
*Gene Expression | 2 | 0.0 |
RNA, Messenger/*metabolism | 5 | 0.0 |
Insulin/blood/*secretion | 3 | 6.0 |
Luteal Phase/physiology | 3 | 14.0 |
Pregnancy Proteins/*blood | 2 | 3.0 |
Alcoholism/*complications | 2 | 10.0 |
Clomiphene/*pharmacology | 3 | 42.0 |
Hypogonadism/blood/*etiology | 2 | 50.0 |
Liver Function Tests | 6 | 3.0 |
Administration, Buccal | 2 | 66.0 |
Phenytoin/therapeutic use | 3 | 30.0 |
*Thyroid Function Tests | 2 | 15.0 |
Thyroid Hormones/*blood | 5 | 8.0 |
Breast Neoplasms/*blood/drug therapy | 3 | 30.0 |
*Europium | 2 | 50.0 |
Iodine Radioisotopes | 3 | 0.0 |
Ovary/*ultrasonography | 2 | 100.0 |
Carcinoma, Hepatocellular/metabolism | 2 | 2.0 |
Methylation | 2 | 0.0 |
Transcortin/*genetics | 2 | 40.0 |
Fatty Acids/blood | 2 | 4.0 |
Femur Neck/physiology | 2 | 18.0 |
Carcinoma, Hepatocellular/*metabolism | 2 | 1.0 |
*Circadian Rhythm | 6 | 2.0 |
Somatomedins/*metabolism | 2 | 8.0 |
Ovulation/*physiology | 4 | 21.0 |
Infant, Newborn/*blood | 2 | 4.0 |
*Pregnancy | 3 | 2.0 |
Anabolic Agents/*therapeutic use | 2 | 33.0 |
Estrogens/metabolism | 3 | 3.0 |
Renin/*blood | 2 | 2.0 |
Cardiovascular Diseases/*etiology | 2 | 6.0 |
Hydrocortisone/metabolism | 2 | 6.0 |
Thyroid Hormones/metabolism | 2 | 18.0 |
Macromolecular Substances | 5 | 0.0 |
Menstruation/drug effects | 2 | 15.0 |
Androgen Antagonists/*pharmacology | 4 | 19.0 |
Contraceptives, Oral, Combined/*pharmacology | 10 | 62.0 |
Estradiol Congeners/pharmacology | 2 | 33.0 |
Norpregnenes/pharmacology | 4 | 44.0 |
Carbimazole/therapeutic use | 2 | 33.0 |
Hyperthyroidism/*blood/drug therapy | 2 | 40.0 |
Hypothyroidism/*blood/drug therapy | 3 | 42.0 |
Ethinyl Estradiol/administration & dosage/therapeutic use | 2 | 100.0 |
Hirsutism/*drug therapy/etiology | 2 | 100.0 |
*Dietary Fats | 2 | 9.0 |
Amenorrhea/*blood/complications | 2 | 50.0 |
Hypothalamus/physiology | 2 | 6.0 |
Liver Cirrhosis/*blood/complications | 2 | 40.0 |
Liver Cirrhosis, Alcoholic/*blood/complications | 2 | 66.0 |
Thyroid Hormones/*metabolism | 3 | 9.0 |
Insulin-Like Growth Factor Binding Protein 1 | 9 | 40.0 |
Thyroxine/pharmacology | 3 | 15.0 |
Sex Hormone-Binding Globulin/chemistry/*genetics/*metabolism | 2 | 100.0 |
Photolysis | 3 | 15.0 |
*Body Weight | 5 | 7.0 |
Uterus/drug effects | 2 | 20.0 |
Liver/drug effects | 2 | 5.0 |
Menopause/metabolism | 5 | 45.0 |
Breast Neoplasms/blood/*etiology | 3 | 75.0 |
Androgens/blood/*metabolism | 2 | 100.0 |
Blood Pressure/drug effects/physiology | 2 | 5.0 |
Carrier Proteins/analysis | 2 | 2.0 |
Discriminant Analysis | 2 | 2.0 |
Climacteric/*blood | 2 | 66.0 |
Estrogens/*administration & dosage | 2 | 40.0 |
Norgestrel/*administration & dosage | 2 | 100.0 |
Premenopause/physiology | 2 | 18.0 |
Plant Extracts/*pharmacology | 2 | 2.0 |
Sex Hormone-Binding Globulin/metabolism/*physiology | 2 | 100.0 |
Contraceptives, Oral, Hormonal/*pharmacokinetics | 2 | 100.0 |
Desogestrel/blood/*pharmacokinetics | 4 | 100.0 |
Ethinyl Estradiol/blood/*pharmacokinetics | 2 | 100.0 |
Liver/drug effects/metabolism | 3 | 4.0 |
Breast Neoplasms/*blood | 13 | 31.0 |
Carrier Proteins/*metabolism | 8 | 1.0 |
Estrogens/urine | 2 | 28.0 |
Antineoplastic Agents/*therapeutic use | 2 | 0.0 |
Atrophy | 2 | 1.0 |
Vagina/*drug effects/pathology | 2 | 40.0 |
Vaginal Smears | 3 | 4.0 |
Androstane-3,17-diol/*analogs & derivatives/blood | 5 | 83.0 |
Sex Hormone-Binding Globulin/drug effects | 3 | 100.0 |
China/epidemiology | 3 | 1.0 |
Climacteric/*drug effects | 5 | 50.0 |
Pregnancy Proteins/*analysis | 3 | 2.0 |
Insulin-Like Growth Factor Binding Proteins | 5 | 13.0 |
*Ovariectomy | 4 | 9.0 |
Testosterone/administration & dosage/blood/*pharmacology | 2 | 66.0 |
Dehydroepiandrosterone/*analogs & derivatives/*blood | 2 | 100.0 |
Glucose/metabolism | 5 | 2.0 |
Contraceptives, Oral, Combined/*pharmacokinetics | 4 | 100.0 |
Physical Endurance/physiology | 2 | 6.0 |
Dietary Fats/*pharmacology | 3 | 4.0 |
Menstrual Cycle/drug effects | 7 | 41.0 |
Transcortin/analysis | 6 | 85.0 |
*Mutagenesis | 2 | 3.0 |
Cells, Cultured | 3 | 0.0 |
Estrogens/*pharmacology | 5 | 6.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Prostatic Hyperplasia/*metabolism | 4 | 8.0 |
Biological Transport/drug effects | 2 | 0.0 |
Polycystic Ovary Syndrome/metabolism | 2 | 40.0 |
Body Height/physiology | 2 | 12.0 |
Lumbar Vertebrae/physiology | 2 | 15.0 |
Physical Fitness | 3 | 12.0 |
Norpregnenes/*metabolism | 4 | 80.0 |
Progesterone Congeners/*metabolism | 2 | 100.0 |
Obesity/blood/complications | 5 | 62.0 |
Hirsutism/blood | 9 | 90.0 |
Liver Cirrhosis/blood | 3 | 7.0 |
Pregnancy/*blood | 4 | 2.0 |
Apolipoproteins/analysis | 2 | 7.0 |
Ethinyl Estradiol/administration & dosage/*pharmacology | 4 | 66.0 |
Phospholipids/blood | 3 | 2.0 |
Polycystic Ovary Syndrome/*blood/classification | 2 | 100.0 |
Corticotropin/*pharmacology | 2 | 11.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Neoplasm Recurrence, Local | 2 | 0.0 |
DNA Probes | 2 | 0.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Liver/enzymology | 2 | 0.0 |
Mice, Inbred DBA | 2 | 0.0 |
Blood Proteins/*metabolism | 12 | 6.0 |
Norpregnenes/blood/*pharmacokinetics | 2 | 100.0 |
Endometriosis/blood/drug therapy | 3 | 100.0 |
Steryl-Sulfatase | 2 | 1.0 |
*Adipose Tissue | 3 | 8.0 |
Insulin/blood/*pharmacology | 2 | 10.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Breast Neoplasms/blood/*therapy | 2 | 50.0 |
Ergometry | 2 | 25.0 |
Exertion/*physiology | 2 | 3.0 |
Sports/*physiology | 2 | 13.0 |
Vitamin D-Binding Protein/blood | 2 | 9.0 |
Contraceptives, Oral, Combined | 3 | 75.0 |
Pregnancy Proteins/*metabolism | 2 | 3.0 |
alpha 1-Antitrypsin/metabolism | 2 | 4.0 |
Adrenal Glands/*drug effects/metabolism | 2 | 40.0 |
Acne Vulgaris/drug therapy | 2 | 66.0 |
Dermatitis, Seborrheic/drug therapy | 2 | 100.0 |
Intrauterine Devices | 2 | 40.0 |
Menstrual Cycle/blood | 5 | 62.0 |
Coronary Disease/*etiology | 2 | 7.0 |
Ovary/drug effects/*physiology | 2 | 28.0 |
Ovulation/drug effects | 5 | 17.0 |
Androgen Antagonists/adverse effects/*therapeutic use | 3 | 75.0 |
Ethinyl Estradiol/adverse effects/*therapeutic use | 4 | 100.0 |
*Thyroidectomy | 2 | 7.0 |
Thyroxine/*adverse effects | 2 | 100.0 |
Gonadal Steroid Hormones/metabolism | 4 | 21.0 |
Liver Cirrhosis, Biliary/*blood | 3 | 60.0 |
Fatty Acids, Nonesterified/blood | 3 | 1.0 |
*Insulin Resistance/physiology | 2 | 66.0 |
Ceruloplasmin/metabolism | 3 | 11.0 |
Transferrin/metabolism | 2 | 1.0 |
Obesity/*complications/physiopathology | 2 | 11.0 |
Endometriosis/blood/*drug therapy | 3 | 60.0 |
Fatty Acids, Nonesterified/*pharmacology | 2 | 22.0 |
Hip | 2 | 50.0 |
Diabetes Mellitus, Type 2/blood | 2 | 5.0 |
Gonadal Steroid Hormones | 2 | 100.0 |
Breast Neoplasms/*etiology | 2 | 10.0 |
Neoplasms, Hormone-Dependent/*etiology | 2 | 100.0 |
Linkage (Genetics) | 2 | 0.0 |
Rats, Inbred F344 | 2 | 0.0 |
Adrenal Glands/*metabolism | 2 | 11.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Obesity/*blood/pathology | 2 | 66.0 |
Aromatase/metabolism | 3 | 21.0 |
Diet, Vegetarian | 2 | 18.0 |
Organ Specificity | 2 | 0.0 |
Menstruation/*blood | 2 | 100.0 |
*Physical Endurance | 3 | 6.0 |
Gonadal Steroid Hormones/*secretion | 2 | 100.0 |
Computer Simulation | 3 | 0.0 |
Ethinyl Estradiol/*pharmacokinetics | 3 | 100.0 |
Levonorgestrel/*pharmacokinetics | 3 | 100.0 |
DNA/genetics | 5 | 0.0 |
*Chromosomes, Human, Pair 17 | 2 | 0.0 |
*Linkage (Genetics) | 2 | 0.0 |
Cell Membrane/*metabolism | 2 | 0.0 |
Cholic Acids | 2 | 22.0 |
Detergents | 2 | 1.0 |
Receptors, Cell Surface/isolation & purification/*metabolism | 2 | 14.0 |
Solubility | 4 | 0.0 |
Testis/*metabolism | 3 | 3.0 |
Thyroid Gland/*metabolism | 2 | 4.0 |
Puberty/*physiology | 3 | 15.0 |
Cross Reactions | 2 | 0.0 |
Contraceptives, Oral/*pharmacokinetics | 2 | 100.0 |
Breast/*growth & development | 2 | 18.0 |
Circadian Rhythm/physiology | 2 | 3.0 |
Affinity Labels/*metabolism | 3 | 42.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
*Diet, Vegetarian | 7 | 53.0 |
Great Britain | 5 | 2.0 |
India/ethnology | 2 | 2.0 |
Algorithms | 3 | 0.0 |
Physical Education and Training/*methods | 2 | 22.0 |
Biological Transport | 5 | 0.0 |
Rats, Inbred Strains | 3 | 0.0 |
Albumins/metabolism | 2 | 1.0 |
Menotropins/therapeutic use | 3 | 21.0 |
Puberty, Precocious/*blood | 4 | 40.0 |
Norpregnenes/*pharmacokinetics | 2 | 100.0 |
Clomiphene/*therapeutic use | 2 | 28.0 |
Estradiol/blood/secretion | 2 | 50.0 |
Follicle Stimulating Hormone/blood/secretion | 3 | 21.0 |
Follicular Phase | 5 | 10.0 |
*Embryo Transfer | 3 | 12.0 |
Adrenal Cortex/*physiopathology | 2 | 66.0 |
Lipoproteins, LDL/blood | 2 | 0.0 |
Androgen-Binding Protein/*genetics | 2 | 33.0 |
Protein S | 5 | 9.0 |
Moscow/epidemiology | 2 | 25.0 |
Sepharose/analogs & derivatives | 2 | 10.0 |
China/ethnology | 2 | 1.0 |
Lignans | 3 | 100.0 |
Uterus/metabolism | 4 | 10.0 |
Random Allocation | 13 | 2.0 |
Ethinyl Estradiol/administration & dosage/pharmacology | 2 | 40.0 |
Hirsutism/blood/*etiology | 2 | 50.0 |
Adaptation, Physiological/*physiology | 2 | 9.0 |
Hypertrophy | 4 | 3.0 |
Endocrine Glands/*physiopathology | 3 | 30.0 |
Menopause/physiology | 2 | 13.0 |
Myocardial Infarction/*blood | 2 | 3.0 |
Radioimmunoassay/methods | 3 | 1.0 |
Body Weight/drug effects | 6 | 3.0 |
Contraceptives, Oral, Combined/adverse effects/*pharmacology | 3 | 75.0 |
Norgestrel/adverse effects/*analogs & derivatives/pharmacology | 2 | 100.0 |
Testosterone/analysis/*blood | 2 | 66.0 |
Polycystic Ovary Syndrome/physiopathology | 3 | 75.0 |
*Menstruation | 3 | 7.0 |
Testosterone/physiology | 2 | 40.0 |
Adipose Tissue/*pathology | 4 | 22.0 |
Finland/epidemiology | 2 | 1.0 |
Women's Health | 4 | 11.0 |
*Orchiectomy | 2 | 11.0 |
Norpregnenes/administration & dosage/*pharmacology | 2 | 100.0 |
Progesterone Congeners/administration & dosage/*pharmacology | 2 | 40.0 |
Metribolone/pharmacology | 2 | 8.0 |
Prostatic Neoplasms | 2 | 3.0 |
Hispanic Americans | 3 | 4.0 |
Mexico/ethnology | 2 | 7.0 |
*Cyproterone Acetate | 3 | 100.0 |
Dexamethasone/therapeutic use | 3 | 16.0 |
Hirsutism/*drug therapy/metabolism | 2 | 100.0 |
Saliva/metabolism | 3 | 10.0 |
Estradiol | 2 | 50.0 |
Models, Chemical | 2 | 0.0 |
Vagina/drug effects | 2 | 28.0 |
Pituitary Gland/*physiopathology | 3 | 10.0 |
*Menarche | 2 | 40.0 |
*Menstrual Cycle | 6 | 9.0 |
Menarche | 5 | 26.0 |
Immunoassay/methods | 3 | 5.0 |
Latex | 2 | 22.0 |
Hypogonadism/blood/*drug therapy | 2 | 40.0 |
Hydroxylation | 2 | 0.0 |
Radiometry | 2 | 11.0 |
Exertion | 3 | 4.0 |
Hirsutism/physiopathology | 2 | 100.0 |
Testosterone/pharmacology | 3 | 5.0 |
Obesity/blood/*pathology | 2 | 100.0 |
Pituitary Hormones, Anterior/blood | 2 | 12.0 |
Sex Hormone-Binding Globulin/chemistry | 2 | 100.0 |
*Contraceptives, Oral, Combined | 2 | 66.0 |
Drug Evaluation | 2 | 0.0 |
Liver/drug effects/*metabolism | 2 | 2.0 |
Hirsutism/drug therapy | 4 | 100.0 |
Carrier Proteins/*analysis | 4 | 4.0 |
Androstane-3,17-diol/*blood | 2 | 100.0 |
Androstenediol/*blood | 3 | 100.0 |
Prostate/metabolism | 5 | 6.0 |
Trypsin | 2 | 1.0 |
Tritium | 6 | 2.0 |
Ethinyl Estradiol/*administration & dosage | 2 | 66.0 |
Insulin-Like Growth Factor I/pharmacology | 2 | 1.0 |
Tumor Cells, Cultured/drug effects/*metabolism | 2 | 8.0 |
Dehydroepiandrosterone/administration & dosage/*pharmacology | 2 | 66.0 |
Circadian Rhythm/*physiology | 2 | 2.0 |
Thyroid Function Tests | 5 | 6.0 |
Thyrotropin/*blood/secretion | 2 | 28.0 |
Cytosol/metabolism | 9 | 1.0 |
Genomic Library | 2 | 0.0 |
*Pseudogenes | 2 | 1.0 |
Ethinyl Estradiol/*administration & dosage/pharmacology | 2 | 66.0 |
Epilepsy/*blood/drug therapy | 4 | 66.0 |
Amenorrhea/blood | 4 | 19.0 |
Apolipoprotein A-I | 4 | 3.0 |
Apolipoproteins A/blood | 4 | 5.0 |
Megestrol Acetate | 2 | 16.0 |
Chemistry | 2 | 0.0 |
Androstanols/*blood | 2 | 100.0 |
Androstenediols/*blood | 2 | 100.0 |
Estradiol/blood/*metabolism | 2 | 50.0 |
Hypogonadism/*etiology | 2 | 50.0 |
Neuromuscular Junction/*physiology | 2 | 11.0 |
Skin/*metabolism | 2 | 1.0 |
Norgestrel/*blood | 3 | 100.0 |
Norpregnenes/*blood | 3 | 100.0 |
Randomized Controlled Trials | 3 | 0.0 |
Ethinyl Estradiol/*blood | 2 | 100.0 |
Norethindrone/*metabolism | 2 | 66.0 |
Norgestrel/*metabolism | 4 | 100.0 |
Breast Diseases/*blood | 2 | 40.0 |
Breast Neoplasms/blood | 2 | 9.0 |
Ammonium Sulfate | 3 | 27.0 |
Precipitation | 6 | 3.0 |
Breast Neoplasms/drug therapy/*metabolism | 2 | 9.0 |
Alopecia/*metabolism | 2 | 100.0 |
Testosterone 5-alpha-Reductase/metabolism | 3 | 42.0 |
Chorionic Gonadotropin/pharmacology | 4 | 3.0 |
Estradiol/*administration & dosage/blood/therapeutic use | 2 | 66.0 |
*Genes, Structural | 2 | 0.0 |
Lipoproteins/*metabolism | 2 | 1.0 |
Menopause/*drug effects | 6 | 85.0 |
Gestrinone/*therapeutic use | 2 | 100.0 |
Norpregnatrienes/*therapeutic use | 2 | 100.0 |
Triglycerides/analysis | 2 | 6.0 |
Acne Vulgaris/chemically induced | 3 | 100.0 |
Androgen-Binding Protein/analysis | 2 | 100.0 |
Estrenes/metabolism | 2 | 40.0 |
Imidazoles/*pharmacology | 2 | 2.0 |
Metribolone | 3 | 37.0 |
Prostate/drug effects/metabolism | 2 | 66.0 |
Testosterone Congeners/metabolism | 2 | 40.0 |
Castration | 5 | 11.0 |
Autoantibodies/blood | 2 | 1.0 |
Centrifugation, Density Gradient | 3 | 0.0 |
Iron/blood | 2 | 2.0 |
Thyroxine-Binding Proteins/analysis | 5 | 35.0 |
Carbamazepine/*pharmacology/therapeutic use | 2 | 66.0 |
Chromatography/methods | 2 | 7.0 |
Fetal Blood/analysis | 3 | 5.0 |
Pregnancy Trimester, Second | 3 | 1.0 |
Testosterone/diagnostic use | 2 | 66.0 |
Glycoproteins/*blood | 2 | 2.0 |
Receptors, Estrogen/*analysis | 4 | 1.0 |
*Positive-Pressure Respiration | 2 | 18.0 |
Quality of Life | 2 | 1.0 |
Norethindrone/*pharmacology | 2 | 40.0 |
Norgestrel/*pharmacology | 5 | 71.0 |
Thyroid Hormones/physiology | 2 | 25.0 |
Protirelin/diagnostic use | 3 | 2.0 |
Hirsutism/complications/*drug therapy | 2 | 100.0 |
Norpregnenes/*therapeutic use | 3 | 50.0 |
Antineoplastic Agents/*adverse effects | 2 | 3.0 |
Hirsutism/*blood/drug therapy | 2 | 100.0 |
Buffers | 2 | 1.0 |
Dextrans | 2 | 4.0 |
Temperature | 4 | 0.0 |
Estradiol/*administration & dosage/blood | 5 | 83.0 |
*Sports | 3 | 9.0 |
Liver Cirrhosis, Alcoholic/*blood | 2 | 14.0 |
Sex Hormone-Binding Globulin/*blood | 15 | 100.0 |
Stress/*physiopathology | 2 | 6.0 |
Hypothyroidism/blood | 3 | 23.0 |
Depression, Chemical | 4 | 2.0 |
Medroxyprogesterone 17-Acetate | 7 | 24.0 |
Sex Hormone-Binding Globulin/blood | 13 | 100.0 |
Contraceptives, Oral, Combined/*pharmacology/therapeutic use | 2 | 100.0 |
Norpregnenes/*pharmacology/therapeutic use | 2 | 66.0 |
Saliva/*analysis | 4 | 33.0 |
*Sex Hormone-Binding Globulin | 4 | 100.0 |
Combined Modality Therapy | 3 | 0.0 |
Prednisolone/*therapeutic use | 2 | 9.0 |
Liver Cirrhosis, Alcoholic/*blood/drug therapy | 2 | 100.0 |
Amiodarone/*adverse effects | 2 | 50.0 |
Statistics | 2 | 0.0 |
Gonadal Steroid Hormones/blood/*genetics | 2 | 100.0 |
Prostatic Neoplasms/*drug therapy | 2 | 5.0 |
Lipoproteins, HDL/*blood | 3 | 1.0 |
Radioligand Assay | 4 | 0.0 |
Norpregnenes/administration & dosage | 2 | 66.0 |
Norpregnenes/*pharmacology | 3 | 30.0 |
Ethinyl Estradiol/*pharmacology/therapeutic use | 2 | 100.0 |
Medroxyprogesterone/analogs & derivatives/pharmacology | 2 | 33.0 |
Tamoxifen/pharmacology | 2 | 2.0 |
*Light | 2 | 5.0 |
*Seasons | 3 | 7.0 |
Mathematics | 2 | 1.0 |
Androgens/*secretion | 2 | 33.0 |
DNA/*analysis | 2 | 0.0 |
Testosterone/*administration & dosage/blood | 2 | 66.0 |
Pituitary Hormones, Anterior/*blood | 2 | 6.0 |
Blood-Brain Barrier | 3 | 5.0 |
Apolipoproteins/*blood | 5 | 3.0 |
Hydrocortisone/pharmacology | 2 | 2.0 |
Ceruloplasmin/analysis | 3 | 10.0 |
Hydrocortisone/*therapeutic use | 2 | 40.0 |
Heat | 5 | 0.0 |
Psychometrics | 2 | 3.0 |
*Quality of Life | 2 | 2.0 |
Estradiol Congeners/administration & dosage | 2 | 66.0 |
Hypogonadism/blood | 3 | 75.0 |
Polycystic Ovary Syndrome/drug therapy | 2 | 100.0 |
*Estrogens, Non-Steroidal | 2 | 66.0 |
Insulin-Like Growth Factor I/*blood | 2 | 20.0 |
Somatomedins/*blood | 2 | 12.0 |
Pregnadienes/*administration & dosage | 2 | 66.0 |
Menotropins/pharmacology | 2 | 15.0 |
Food Habits | 2 | 7.0 |
Apolipoprotein A-II | 2 | 4.0 |
Coronary Disease/blood | 2 | 7.0 |
Sweden | 2 | 0.0 |
Pituitary Gland/*physiology | 2 | 8.0 |
Liver/pathology | 2 | 1.0 |
Pregnancy Proteins/analysis | 3 | 37.0 |
Receptors, Steroid/*analysis | 2 | 8.0 |
Transcortin/blood | 3 | 100.0 |
Endometrium/drug effects | 2 | 50.0 |
Liver Cirrhosis/*blood | 3 | 8.0 |
Ceruloplasmin/*metabolism | 2 | 7.0 |
Contraceptives, Oral, Combined/pharmacology | 2 | 40.0 |
Chorionic Gonadotropin/*pharmacology | 3 | 5.0 |
Computers | 2 | 4.0 |
Pregnadienes/*pharmacology | 2 | 28.0 |
Delayed-Action Preparations | 2 | 1.0 |
Vagina | 2 | 25.0 |
*Castration | 3 | 30.0 |
Diethylstilbestrol/therapeutic use | 2 | 22.0 |
Administration, Topical | 5 | 4.0 |
Vagina/*drug effects | 2 | 100.0 |
Mastectomy | 2 | 2.0 |
Pregnadienes/*therapeutic use | 2 | 33.0 |
17-Ketosteroids/urine | 3 | 42.0 |
Hair/growth & development | 2 | 33.0 |
Lipoproteins, HDL Cholesterol | 2 | 4.0 |
Arteries | 2 | 3.0 |
Serum Globulins/*analysis | 4 | 50.0 |
Amniotic Fluid/*analysis | 2 | 2.0 |
Protein Biosynthesis | 2 | 0.0 |
Denmark | 2 | 1.0 |
Brain/*metabolism | 2 | 0.0 |
Diethylstilbestrol/*therapeutic use | 2 | 33.0 |
Intercellular Signaling Peptides and Proteins/blood | 2 | 7.0 |
Androstenedione/*metabolism | 3 | 50.0 |
Lynestrenol/pharmacology | 2 | 100.0 |
Progesterone Congeners/*pharmacology | 2 | 15.0 |
*Continental Population Groups | 2 | 7.0 |
Testosterone | 2 | 100.0 |
Estrone/*analogs & derivatives/blood | 2 | 66.0 |
Prostatic Neoplasms/*blood/drug therapy | 2 | 40.0 |
Serum Globulins/*metabolism | 3 | 42.0 |
Hyperinsulinism/complications | 2 | 20.0 |
Receptors, Cell Surface/metabolism | 2 | 0.0 |
